Susan Calcaterra1, Jason Glanz, Ingrid A Binswanger. 1. Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, United States. Susan.Calcaterra@ucdenver.edu
Abstract
BACKGROUND: Pharmaceutical opioid related deaths have increased. This study aimed to place pharmaceutical opioid overdose deaths within the context of heroin, cocaine, psychostimulants, and pharmaceutical sedative hypnotics examine demographic trends, and describe common combinations of substances involved in opioid related deaths. METHODS: We reviewed deaths among 15-64 year olds in the US from 1999-2009 using death certificate data available through the CDC Wide-Ranging Online Data for Epidemiologic Research (WONDER) Database. We identified International Classification of Disease-10 codes describing accidental overdose deaths, including poisonings related to stimulants, pharmaceutical drugs, and heroin. We used crude and age adjusted death rates (deaths/100,000 person years [p-y] and 95% confidence interval [CI] and multivariable Poisson regression models, yielding incident rate ratios; IRRs), for analysis. RESULTS: The age adjusted death rate related to pharmaceutical opioids increased almost 4-fold from 1999 to 2009 (1.54/100,000 p-y [95% CI 1.49-1.60] to 6.05/100,000 p-y [95% CI 5.95-6.16; p<0.001). From 1999 to 2009, pharmaceutical opioids were responsible for the highest relative increase in overdose death rates (IRR 4.22, 95% CI 3.03-5.87) followed by sedative hypnotics (IRR 3.53, 95% CI 2.11-5.90). Heroin related overdose death rates increased from 2007 to 2009 (1.05/100,000 persons [95% CI 1.00-1.09] to 1.43/100,000 persons [95% CI 1.38-1.48; p<0.001). From 2005-2009 the combination of pharmaceutical opioids and benzodiazepines was the most common cause of polysubstance overdose deaths (1.27/100,000 p-y (95% CI 1.25-1.30). CONCLUSION: Strategies, such as wider implementation of naloxone, expanded access to treatment, and development of new interventions are needed to curb the pharmaceutical opioid overdose epidemic.
BACKGROUND: Pharmaceutical opioid related deaths have increased. This study aimed to place pharmaceutical opioid overdose deaths within the context of heroin, cocaine, psychostimulants, and pharmaceutical sedative hypnotics examine demographic trends, and describe common combinations of substances involved in opioid related deaths. METHODS: We reviewed deaths among 15-64 year olds in the US from 1999-2009 using death certificate data available through the CDC Wide-Ranging Online Data for Epidemiologic Research (WONDER) Database. We identified International Classification of Disease-10 codes describing accidental overdose deaths, including poisonings related to stimulants, pharmaceutical drugs, and heroin. We used crude and age adjusted death rates (deaths/100,000 person years [p-y] and 95% confidence interval [CI] and multivariable Poisson regression models, yielding incident rate ratios; IRRs), for analysis. RESULTS: The age adjusted death rate related to pharmaceutical opioids increased almost 4-fold from 1999 to 2009 (1.54/100,000 p-y [95% CI 1.49-1.60] to 6.05/100,000 p-y [95% CI 5.95-6.16; p<0.001). From 1999 to 2009, pharmaceutical opioids were responsible for the highest relative increase in overdose death rates (IRR 4.22, 95% CI 3.03-5.87) followed by sedative hypnotics (IRR 3.53, 95% CI 2.11-5.90). Heroin related overdose death rates increased from 2007 to 2009 (1.05/100,000 persons [95% CI 1.00-1.09] to 1.43/100,000 persons [95% CI 1.38-1.48; p<0.001). From 2005-2009 the combination of pharmaceutical opioids and benzodiazepines was the most common cause of polysubstance overdose deaths (1.27/100,000 p-y (95% CI 1.25-1.30). CONCLUSION: Strategies, such as wider implementation of naloxone, expanded access to treatment, and development of new interventions are needed to curb the pharmaceutical opioid overdose epidemic.
Authors: Lauretta E Grau; Nabarun Dasgupta; Alison Phinney Harvey; Kevin Irwin; Anthony Givens; Mark L Kinzly; Robert Heimer Journal: Am J Addict Date: 2007 May-Jun
Authors: K Tardiff; P M Marzuk; A C Leon; L Portera; N Hartwell; C S Hirsch; M Stajic Journal: Am J Drug Alcohol Abuse Date: 1996-05 Impact factor: 3.829
Authors: Lynn R Webster; Susan Cochella; Nabarun Dasgupta; Keri L Fakata; Perry G Fine; Scott M Fishman; Todd Grey; Erin M Johnson; Lewis K Lee; Steven D Passik; John Peppin; Christina A Porucznik; Albert Ray; Sidney H Schnoll; Richard L Stieg; Wayne Wakeland Journal: Pain Med Date: 2011-06 Impact factor: 3.750
Authors: Su Albert; Fred W Brason; Catherine K Sanford; Nabarun Dasgupta; Jim Graham; Beth Lovette Journal: Pain Med Date: 2011-06 Impact factor: 3.750
Authors: Leanne M Yanni; Jessica L McKinney-Ketchum; Sarah B Harrington; Christine Huynh; Saad Amin Bs; Robin Matsuyama; Patrick Coyne; Betty A Johnson; Mark Fagan; Linda Garufi-Clark Journal: J Grad Med Educ Date: 2010-06
Authors: Alexandria Macmadu; Jennifer J Carroll; Scott E Hadland; Traci C Green; Brandon D L Marshall Journal: Addict Behav Date: 2017-01-06 Impact factor: 3.913
Authors: David Frank; Pedro Mateu-Gelabert; Honoria Guarino; Alex Bennett; Travis Wendel; Lauren Jessell; Anastasia Teper Journal: Int J Drug Policy Date: 2014-07-31
Authors: Amber L Bahorik; Derek D Satre; Andrea H Kline-Simon; Constance M Weisner; Kelly C Young-Wolff; Cynthia I Campbell Journal: Subst Abus Date: 2017-09-06 Impact factor: 3.716
Authors: Christopher Rowe; Glenn-Milo Santos; Eric Vittinghoff; Eliza Wheeler; Peter Davidson; Philip O Coffin Journal: Addiction Date: 2015-08 Impact factor: 6.526
Authors: Juan A A Luna; Roland S Moore; Daniel J Calac; Joel W Grube; Richard P McGaffigan Journal: J Rural Health Date: 2018-10-04 Impact factor: 4.333